Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections.(2) The European Medicines Agency has approved the use of infliximab biosimilar CT-P13 for psoriasis by extrapolating efficacy from studies in rheumatoid arthritis and ankylosing spondilytis.(3,4) This article is protected by copyright. All rights reserved
Gisondi, P., Bianchi, L., Conti, A., Dapavo, P., Malagoli, P., Piaserico, S., et al. (2017). Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry. BRITISH JOURNAL OF DERMATOLOGY, 177(6), 325-326 [10.1111/bjd.15659].
Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.
BIANCHI, LUCA;
2017-01-01
Abstract
Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections.(2) The European Medicines Agency has approved the use of infliximab biosimilar CT-P13 for psoriasis by extrapolating efficacy from studies in rheumatoid arthritis and ankylosing spondilytis.(3,4) This article is protected by copyright. All rights reserved| File | Dimensione | Formato | |
|---|---|---|---|
|
gisondi.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
77.99 kB
Formato
Adobe PDF
|
77.99 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
